



#9

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:
Kevin Leon Gaston et al.

Serial No.: 10/047,990

Filed: January 14, 2002

For: METHODS OF INDUCING CELL DEATH

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: WIRO:016US

**CERTIFICATE OF MAILING
37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box Missing Parts, Commissioner for Patents, Washington, DC 20231, on the date below.

August 15, 2002

Date

Mark B. Wilson

**SUBMISSION OF FOREIGN PRIORITY DOCUMENT AND
CLAIM FOR FOREIGN PRIORITY PURSUANT TO 37 C.F.R. § 1.55**

Commissioner for Patents
Washington, D.C. 20231


Sir:

Applicants respectfully claim priority to Great Britain Patent Application No. 9916363.6, filed July 13, 1999, for the above-referenced application and submit herewith a certified copy of the Great Britain priority patent application.



While it is believed that no fees under 37 C.F.R. §§ 1.16 to 1.21 are occasioned by the filing of this request, should the Commissioner determine otherwise, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/WIRO:016US.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'MBW', is written over the typed name 'Mark B. Wilson'.

Mark B. Wilson
Reg. No. 37,259
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: August 15, 2002





INVESTOR IN PEOPLE


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 8 February 2002

13 JUL 1999

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

THE PATENT OFFICE
A
13 JUL 1999
RECEIVED BY HAND

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

JPD/SMH/UNIBR.39

2. Patent application number

(The Patent Office will fill in this part)

9916363.6

3. Full name, address and postcode of the or of each applicant (underline all surnames)

THE UNIVERSITY OF BRISTOL
Senate House
Tyndall Avenue
BRISTOL
BS8 1TH

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

ENGLAND

402244201

4. Title of the invention

METHODS OF SUPPRESSING CELL GROWTH

5. Name of your agent (if you have one)

WITHERS & ROGERS

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Goldings House
2, Hays Lane
LONDON
SE1 2HW

Patents ADP number (if you know it)

1776001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

YES

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description

Claim(s)

Abstract

Drawing(s)

21 + 21

10. If you are also filing any of the following, state how many against each item.

Priority documents


Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)Request for preliminary examination and search (*Patents Form 9/77*)Request for substantive examination (*Patents Form 10/77*)Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature



Date

13/07/99

12. Name and daytime telephone number of person to contact in the United Kingdom

J P DEAN - Tel: 0117 925 3030

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Methods of Inducing Cell Death

This invention relates to methods of inducing cell death and preferably, though not exclusively to methods of killing cells using E2 and/or E7 proteins from papillomaviruses.

Papillomaviruses (PV), viruses of the family Papoviridae, are DNA viruses which have double stranded circular DNA containing a number of genes including the E2, E6 and E7 genes. They infect epithelial cells and generally induce the formation of benign hyperproliferative lesions. Millions of men and women have a genital tract infection of one of at least 95 types of human papillomavirus (HPV) leading to genital warts. However, some papillomavirus types are associated with more serious conditions such as cancer. For example, HPV types 16 and 18 have been linked to cervical cancer in women (zur Hausen, H (1991) *Virology*, **184**, 9-13) and bovine papillomavirus (BPV) types 2 and 4 have been linked to bladder cancer and cancer of the upper alimentary canal respectively, in cattle (Campo, M. S., *et al* (1992) *Cancer Res.* **52**, 6898-6904, Campo, M. S., *et al.* (1994) *Carcinogenesis*, **15**, 1597-1601). Human cervical cancer cells express the viral E6 and E7 oncogenes and the products of these genes increase cell proliferation and promote cell immortalisation (Crook, T., and Vousden, K. H. (1996) *Papillomavirus Reviews: Current Research on Papillomaviruses* (Lacey, C., ed) pp. 55-60, Leeds University Press, Leeds). The human papillomavirus E2 gene, or lack thereof is also thought to play a major role in the development of cervical cancer with PV-infected cells. Most cervical cancers contain chromosomally integrated copies of the HPV genome in which the viral E2 gene has been disrupted as a result of the opening of the viral circular DNA (Baker, C. C., *et al.* (1987) *J. Virol.*, **61**, 962-971). Furthermore, mutations in the E2 gene increase the immortalisation capacity of HPV 16 (Romanczuk, H., and Howley, P. M. (1992) *Proc. Natl. Acad. Sci. USA.* **89**, 3159-3163).

The papillomavirus E2 genes encode sequence-specific DNA binding proteins that regulate viral gene expression and which are also required for viral DNA replication (Thierry, F. (1996) *Papillomavirus reviews: current research on papillomaviruses* (Lacey, C., ed) pp. 21-29, Leeds University Press, Leeds). The E2 proteins bind as dimers to multiple copies of an inverted repeat sequence found within the viral long control region

(LCR). Depending on the particular PV virus, and the particular E2 protein being studied, the binding of E2 to these sites can either activate or repress transcription of the E6 and E7 oncogenes. For example, the HPV 16 E2 protein activates transcription from the P97 promoter located at the 3' end of the HPV 16 LCR which causes increased transcription of the E6 and E7 oncogenes whereas, under exactly the same conditions, the BPV1 E2 protein represses P97 promoter activity (Boulvard, V., *et al.* (1994) *EMBO J.* 13, 5451-5459, Kovelman, R *et al* (1996) *Virol*, 70, 7549-7560). Each subunit of the E2 dimer contains two domains which are separated by a flexible hinge region: the N-terminal domain of each subunit mediates the regulation of viral transcription whereas the C-terminal domain mediates DNA binding and dimerisation (Giri, I., and Yaniv, M (1988) *EMBO J.*, 7, 2823-2329). In BPV, truncated E2 proteins that lack the N-terminal transcriptional domain are also expressed. These truncated E2 proteins (E2-TR) can repress viral transcription and can also form transcriptionally inactive heterodimers with full length E2 (Barsoum, J. *et al.* (1992) *J. Virol.*, 66, 3941-3945).

The E2 proteins from HPV 16, HPV 18, and BPV1 all have dramatic effects on the proliferation and survival of cervical carcinoma cell lines. We have shown expression of the HPV 16 E2 protein in modified SiHa cells. SiHa cells are an HPV 16-transformed cell line that contains a single disrupted copy of the E2 gene. We produced SiHa-E2 stable cell lines that express the HPV16 E2 protein under the control of the heavy metal-inducible metallothionein promoter. The inclusion of E2 expression in these cells using heavy metals results in cell death via apoptosis (Sanchez-Perez, A. *et al.* (1997) *J. Gen. Virol.*, 78, 3009-3018). The E2-induced cell death showed several of the features characteristic of apoptosis including: blebbing of the plasma membrane, chromatin condensation, and the appearance of cell fragments with sub-G0 DNA content. Similarly, the HPV 18 E2 protein induces apoptosis in HeLa cells, an HPV 18-transformed cell line that also contains disrupted copies of the E2 gene (Desaintes, C., *et al.* (1997) *EMBO J.* 16, 504-514). Expression of the BPV1 E2 protein in either SiHa or HeLa cells has been shown to suppress proliferation, in part at least, by blocking the cells' transition from G1 to S phase (Hwang, E. S., *et al* (1993) *J. Virol.*, 67, 3720-3729, Dowhanick, J. J., *et al.* (1995) *J. Virol.*, 69, 7791-7799, Hwang, E. S., *et al* (1996) *Oncogene*, 12, 795-803). Since the proliferation assays used in these experiments scored colony formation after several days in culture, BPV1 E2 might also induce apoptosis in these cell lines.

There is also some evidence to suggest that the E2 proteins might have effects on non-HPV-transformed cells. Expression of the HPV 31 E2 protein in HPV-negative normal human foreskin keratinocytes (NHK cells) using a recombinant adenovirus, resulted in S-phase cell cycle arrest, and the appearance of cells with subG0 DNA content; a characteristic feature of apoptotic cell death (Frattoni, M. G., *et al* (1997) *EMBO J.*, **16**, 318-331). However, BPV1 E2 has no effect on the proliferation of C33a cells, an HPV-negative cervical carcinoma cell line, or SAOS cells, an HPV-negative osteosarcoma cell line (Dowhanick, J. J. *et al.* (1995) *J. Virol.* **69**, 7791-7799). Furthermore, the HPV 18 E2 protein has no effect on the levels of apoptosis in C33a cells, SAOS cells, or HaCat cells, an HPV-negative spontaneously immortalised human keratinocyte cell line (Desaintes, C., *et al* (1997) *EMBO J.*, **16**, 504-514).

At present, there is no model that can explain satisfactorily the effects of the E2 proteins on cell proliferation. BPV1 E2 and HPV 18 E2 have been shown to repress transcription of the HPV 18 E6 and E7 oncogenes (Hwang, E. S. *et al* (1993) *J. Virol.* **67**, 3720-3729, Desaintes, C., *et al* (1997) *EMBO J.*, **16**, 504-514).

The tumour suppression protein p53 is well characterised. There are many mutants of p53 as well as p53-related genes such as p73 and p63 (White, E. and Prives, C., *Nature*, **399**, June 1999). The E6 protein binds to the tumour suppressor protein p53 and this interaction results in a decrease in the half-life of p53 within cells (Werness, B. A. *et al* (1990) *Science*, **248**, 76-79, Scheffner, M., *et al.*, (1990) *Cell*, **63**, 1129-1136, Lechner, M. S. *et al* (1992) *EMBO J.*, **11**, 3045-3052, Hubbert, N. L. *et al* (1992) *J. Virol.*, **66**, 6237-6241). Since p53 can block cell cycle progression and/or induce apoptosis (Gottlieb, T. M. and Oren, M. (1998) *Seminars in Cancer Biol.*, **8**, 359-368), decreased levels of E6 might be expected to lead to increased levels of p53 and increased levels of cell cycle arrest and/or cell death (shown schematically in Fig. 1). In keeping with this view, expression of BPV1 E2 in HeLa cells appears to stabilise p53 (Hwang, E. S. *et al* (1993) *J. Virol.* **67**, 3720-3729, Desaintes, C., *et al.* (1997) *EMBO J.*, **16**, 504-514). However, E2-TR also represses transcription of E6 and E7 in these cells, but this truncated E2 protein can neither stabilise p53, nor induce apoptosis (Desaintes, C., *et al.* (1997) *EMBO J.* **16**, 504-514). This suggests that the N-terminal transcription regulation domain is responsible for these effects and that the repression of E6 transcription by E2 is not the critical event. In

addition, the expression of HPV 31 E2 in NHK cells appears to de-stabilise p53 (Frattoni. M. G. *et al* (1997) *EMBO J.* **16**. 318-331).

The E7 protein binds to the Rb tumour suppressor protein and the Rb-related proteins p107 and p130 (Dyson, N., *et al* (1989) *Science*, **243**, 934-937, Hu, T., *et al* (1995) *Int. J. Oncology*. **6**. 167-174). The binding of E7 to Rb brings about the release of E2F proteins from Rb-E2F complexes and is also thought to target Rb for ubiquitin-dependent proteolysis (Boyer. S. N. *et al* (1996) *Cancer Res.* **56**. 4620-3624, Jones, D. L. and Munger, K. (1997) *J. Virol.*, **71**, 2905-2919, Virology, **239**, 97-107). When released from Rb, members of the E2F family of transcription factors activate the transcription of genes required for S-phase and the over-expression of E2F-1 can induce apoptosis in serum-starved cells (Wu X., and Levine, A. J. (1994) *Proc. Natl. Acad. USA* **91**. 3602-3606, Qin. X. Q., *et al.* (1994) *Proc. Natl. Acad. Sci. USA*. **91**. 10918-10922). The repression of E7 transcription by E2 might therefore be expected to reduce the levels of free E2F, leading to cell cycle arrest (see the accompanying Fig. 1).

Specifically, Fig. 1 is a schematic representation of some of the possible routes from the HPV 16 E2 protein to the induction of apoptosis. The bottom line represents the integrated HPV genome and the bent arrow indicates the P97 promoter. The E2 protein regulates transcription of the HPV 16 E6 and E7 genes (open boxes). E6 binds to p53 and this reduces the half-life of p53 within the cell. E7 binds to Rb and brings about the release of E2F. Both p53 and E2F can bring about apoptosis. Note that E2 could also induce apoptosis independently of its effects on transcription of E6 and E7.

Expression of BPV1 E2 protein in HeLa cells is accompanied by decreased levels of E2F-1 mRNA and protein, and by reduced expression of E2F-dependent genes (Hwang, E. S. *et al* (1996) *Oncogene*, **12**. 795-803). However, expression of the HPV 16 E2 protein in SiHa cells is accompanied by increased E2F activity (Sanchez-Perez, A. M. *et al* (1997) *J. Gen. Virol.* **78**. 3009-3018). Furthermore, over-expression of the HPV 31 E2 protein in NHK cells is accompanied by an increase in E2F-1 mRNA levels (Frattoni. M. G. *et al* (1997) *EMBO J.* **16**. 318-331). Another complication is that unlike BPV1 E2, which represses transcription, the HPV 16 and HPV 18 E2 proteins have both been shown to activate transcription of the HPV 16 E6 and E7 oncogenes (Bouvard, V., *et al* (1994) *EMBO J* **13**

5451-5459, Kovelman, R., *et al* (1996) *Viol.* **70**. 7549-7560). Any increase in the levels of E7 might be expected to result in increased levels of free E2F and this could in turn lead to cell death (Sanchez-Perez, A. M. *et al* (1997) *J. Gen. Virol.* **78**. 3009-3018).

Models that seek to explain the effects of E2 proteins on cell proliferation via transcriptional repression or activation of the E6 and E7 genes, are obviously limited to HPV-positive cells. However, the HPV 31 E2 protein appears to induce apoptosis in HPV-negative NHK cells (Frattini, M. G. *et al* (1997) *EMBO J.* **16**. 318-331). Moreover, mutations in the HPV 16 LCR that block the binding of E2 to the promoter proximal E2 sites and prevent E2-mediated repression of E6 and E7 transcription, do not fully relieve the negative effects of E2 on transformation efficiency (Romanczuk, H., and Howley. P. M. (1992) *Proc. Natl. Acad. Sci. USA.* **89**., 3159-3163). These reports suggest that E2 might influence cell proliferation independently of its effects on the transcription of E6 and E7. To address this issue we have expressed the HPV 16 E2 protein in a variety of transiently transfected cell lines. We have shown that this E2 protein can unexpectedly induce apoptosis in both HPV-transformed and non-HPV-transformed cell lines. In addition we have shown that the HPV 16 E2-induced apoptosis is p53-dependent and that the DNA binding activity of this E2 protein is not required for the induction of cell death.

WO98/01148 (Harvard) discloses methods and compositions for interfering with the proliferation of cells infected with and/or transformed by PV. There is no disclosure of the use of E2 to kill HPV-negative cells, the p53 status of the cells, the induction of apoptosis in the treated cells, or the generation of an immune response to PV.

WO94/04686 (Biogen) describes a method for the delivery of proteins, including HPV E2 polypeptides, to cells based on the HIV TAT protein.

WO92/12728 (Biogen) discloses non-functional E2-derived polypeptides, specifically E2 *trans*-activation repressors, which dimerise with normal E2 and block its function in HPV-infected cells.

According to one aspect of the invention there is provided a method of inducing apoptosis of p53-, or p53 mutant-, or p53 related gene positive cells comprising those cells with a PV E2 and/or E7 protein or a functional portion or derivative thereof or supplying to the cells a

DNA sequence encoding a PV E2 and/or E7 protein or a functional portion or derivative thereof.

According to another aspect of the invention, there is provided a method of killing PV positive cells comprising contacting those cells with a PV E2 and/or E7 protein or a functional portion or derivative thereof or supplying to the cells a DNA sequence encoding a PV E2 and/or E7 protein or a functional portion or derivative thereof.

According to a further aspect of the invention, there is provided a method of killing cells infected with an oncogenic virus comprising contacting those cells with a PV E2 and/or E7 protein or a functional portion or derivative thereof or supplying to the cells a DNA sequence encoding a PV E2 and/or E7 protein or a functional portion or derivative thereof.

According to a further aspect of the invention, there is provided a method of killing oncogenic cells or oncogenic precursor comprising contacting those cells with a PV E2 and/or E7 protein or a functional portion or derivative thereof or supplying to the cells a DNA sequence encoding a PV E2 and/or E7 protein or a functional portion or derivative thereof.

According to a further aspect of the invention there is provided a method of treating cervical cancer comprising contacting cervical cells of a subject with E2 and/or E7 or a functional portion thereof or supplying to the cells a DNA sequence encoding a PV E2 and/or E7 protein or a functional portion thereof.

Such a method is advantageous in that a immune response against HPV may be produced by the E2 or E7 on derivative in addition to causing death of the cancer cells.

In this invention, the use of E2 protein and functional derivatives or portions thereof are preferred although the use of E7 protein and functional derivatives or portions thereof are contemplated.

The E2 proteins from HPV 16, HPV 18, and BPV1 all have dramatic effects on the proliferation and/or survival of cervical carcinoma cell lines (Sanchez-Perez, A. M. *et al* (1997) *J. Gen. Virol.*, 78. 3009-3018, Desaintes, C. *et al* (1997) *EMBO J.* 16. 504-514, Hwang, E. S., *et al* (1993) *J. Virol.* 67. 3720-3729). We previously proposed that the

HPV 16 E2 protein induces apoptosis in HPV 16-transformed SiHa cells by activating transcription of the viral E7 gene (Sanchez-Perez, A. M. *et al* (1997) *J. Gen. Virol.* **78**, 3009-3018). In contrast, others have proposed that the HPV 18 E2 protein induces apoptosis in HPV 18-transformed HeLa cells by repressing transcription of the viral E6 and E7 genes (Desaintes, C., *et al* (1997) *EMBO J.* **16**, 504-514). Here we have shown that the HPV 16 E2 protein induces apoptosis in two non-HPV-transformed cell lines, supporting the demonstration that the HPV 31 E2 protein appears to induce apoptosis in HPV-negative NHK cells (Frattoni, M. G. *et al* (1997) *EMBO J.* **16**, 318-331). These data show that neither of the above mechanisms can be entirely correct. Either the E2 proteins induce apoptosis independently of the HPV genome or these proteins induce apoptosis via two pathways: one requiring other HPV proteins and one independent of other HPV proteins.

The E7 protein has been extensively studied, primarily as an oncoprotein, but also as an inducer of apoptosis. For example, E7 has been shown to sensitise keratinocytes to undergo both spontaneous apoptosis and apoptosis in response to tumour necrosis factor α (Stoppler, H. *et al* (1998) *Oncogene*. **17**, 1207-1214). There is evidence to suggest that E7-induced apoptosis occurs via p53-dependent and p53-independent pathways (Howes, K. A. *et al* (1994) *Genes and Dev.* **8**, 1300-1310, Pan. H., and Griep. A. E. (1994) *Genes and Dev.* **8**, 1285-1299, Stoppler. H. *et al* (1998) *Oncogene* **17**, 1207-1214). Here we have shown that in HeLa cells, over-expression of the HPV 16 E7 protein induces apoptosis. The E7-induced apoptosis can be abrogated by over-expression of the HPV 16 E6 protein, or by expression of a trans-dominant negative mutant of p53. These findings strongly suggest that the HPV 16 E7 protein induces p53-dependent apoptosis in these cells. We have shown that, like E7, the HPV 16 E2 protein induces apoptosis in HeLa cells and that this apoptosis is p53-dependent. Both E7 and E2 induce apoptosis in cells that contain the HPV 16 E6 gene. Given that E6 binds to p53 and that this interaction results in a decrease in the half-life of p53, this might seem remarkable. However, p53 activity has been demonstrated in several HPV-positive cell lines (Butz, K., *et al* (1995) *Oncogene*, **10**, 927-936, Desaintes, C., *et al* (1997) *EMBO J.* **16**, 504-514).

We have shown that the sequence-specific DNA binding activity of the HPV 16 E2 protein is not required for the induction of apoptosis in HeLa cells. In contrast, the N-terminal domain, including the transcription activation domain and the hinge region, is

essential for the promotion of cell death. Growth arrest by BPV1 E2 requires a functional DNA binding domain and a functional transcription activation domain (Goodwin, E. C. *et al* (1998) *J. Virol.* **72**. 3925-3934). These data suggest that the induction of apoptosis by the HPV 16 E2 protein and the induction of growth arrest by the BPV1 E2 protein, are brought about by two separate pathways. Presumably, growth arrest brought about by the BPV1 E2 protein requires transcriptional regulation of the integrated HPV oncogenes. Thus, BPV1 E2-induced growth arrest could be the result of transcriptional repression of the integrated E6 and E7 genes (Goodwin, E. C. *et al* (1998) *J. Virol.* **72**. 3925-3934). Repression of E6 transcription by BPV E2 would be expected to result in increased levels of p53 and this could lead to p53-dependent apoptosis (Hwang, E. S. *et al* (1996) *Oncogene* **12**. 795-803, Desaintes, C. *et al* (1997) *EMBO J.* **16**. 504-514). In contrast, the induction of apoptosis by HPV 16 E2 occurs independently of its DNA binding activity and independently of the presence of integrated HPV sequences.

Using E2 heterodimers we have shown that two functional transcription activation domains are required for the induction of apoptosis by the HPV 16 E2 protein. Similar heterodimer experiments with BPV1 E2 and BPV1 E2-TR showed that two functional activation domains are required for efficient transcription activation (Barsoum, J. *et al* (1992) *J. Virol.* **66**, 3941-3945). Why two activation domains per E2 dimer should be essential for either transcription activation, or the induction of apoptosis, is not presently known.

We have shown that the HPV 16 E2 protein brings about apoptosis in the absence of other HPV gene products and that this E2-induced apoptosis is p53-dependent. Integration of the HPV genome into the host chromosome and the consequent disruption of the E2 gene removes this pro-apoptotic signal. Since the integrated HPV sequences continue to produce the E6 and E7 proteins, these cells continue to proliferate and are likely to form cervical tumours.

In this specification, the following expressions are used with the following, non-limiting meanings, given by of explanation:

1. "PV positive" means that a cell has been infected or transformed by PV and "PV negative" has an opposite meaning.

2. "Protein" and "polypeptide" are used interchangeably although "protein" may generally be considered to be a naturally-occurring polypeptide.

Methods of inducing cell death and products in accordance with the invention will now be described, by way of example only, with reference to the further accompanying drawings, Figures 2 to 12 in which:

Figure 2 shows the effect of HPV 16 E2 on HeLa cells.

Figure 3 shows the results of experiments using E2 and E7 to induce apoptosis in HeLa cells.

Figure 4 shows the results of experiments which demonstrate that E2- and E7-induced apoptosis is p53-dependent;

Figure 5 shows the results of experiments which show that the truncated E2 protein E2Ct mutated at N296, K299, and R304 folds and dimerises but fails to bind DNA;

Figure 6 shows the results of experiments which show that DNA binding is not required for the induction of apoptosis, but that the N-terminal transcription regulation domain is required;

Figure 7 shows the results of experiments which demonstrate that E2-E2Ct heterodimers do not induce apoptosis; and

Figure 8 shows schematically the proteins used in the following experiments;

Figure 9 shows the DNA and amino acid sequences of HPV16E2;

Figure 10 shows the DNA and amino acid sequences of HPV E2DBM;

Figure 11 shows the DNA and amino acid sequences of E2Ct;

Figure 12 shows the DNA and amino acid sequence of E2CtDBM.

1) Experimental procedures - General

a. Plasmids.

The plasmids pCB6+p53 and pCB6+p53173L express wild-type and mutant p53, respectively, and were kindly supplied by Dr Moshe Oren and Dr Andy Phillips. Plasmid pCMX-GFP3 expresses green fluorescent protein and was kindly supplied by Dr Jeremy Tavaré. The pWEB plasmid was made by removing an *XhoI-EcoRI* fragment carrying the CMV promoter from pUHD 15-1 and using this fragment to replace the tetracycline-inducible promoter in pUHD 10-3. The HPV 16 E2 (Fig. 9), E6, and E7 expression plasmids were produced by cloning the appropriate HPV sequences obtained from HPV 16 genomic DNA into a unique *EcoRI* site in pWEB, immediately downstream of the CMV promoter.

The E2 gene was amplified by PCR (94°C for 1 minute, 53°C for 3 minutes, and 72°C for 1 minutes, for 30 cycles) from HPV 16 DNA template using the oligonucleotide primers E25' 5' CTACGAATTCATGGAGACTCTTTGCCAACG 3' and E23' 5' GATAGAATTCTCATATAGACATAAATCCAG 3'. These primers place *EcoRI* restriction sites (highlighted in bold throughout) at the 5' and 3' ends of the E2 coding sequence. The PCR product was cloned into the *EcoRI* site of pWEB and sequenced using a panel of E2-specific sequencing primers to check for the occurrence of any point mutations.

The E6 gene was amplified by PCR (95° for 1 minute, 52° for 1 minute, and 68°C for 2 minutes, for 30 cycles) from HPV 16 template using the primers E65' 5' TGAGAATTCATGCACCAAAAGAGAACTGCAATGTTTCAG 3' and E63' 5' ATCGAATTCTTACAGCTGGGTTTCTCTACG 3' which have *EcoRI* sites. The PCR product was cloned into the *EcoRI* site of pWEB and sequenced using a panel of E6-specific sequencing primers.

The E7 gene was amplified by PCR (94°C for 1 minute, 54°C for 2 minutes, and 72°C for 1 minute, for 30 cycles) from a HPV 16 template using the primers E75' 5' TCGGAATTCATGCATGGAGATACACCTAC 3' and E73' 5' AGCGAATTCTT

ATGGTTTCTGAGAACAGATGG 3' which have *Eco* RI sites. The PCR product was cloned into pWEB and sequenced using the E7 PCR primers.

Mutated E2 constructs were generated using PCR. The plasmid pWEB-E2DBDm expresses a mutated E2 protein in which three amino acids within the E2 DNA binding domain (N296, K299, and R304) have been replaced by alanines. The mutations were introduced by PCR (94°C for 1 minute, 55°C for 1 minute, and 68°C for 1 minute, for 30 cycles) using the primers pWEB5' 5' ACCTCCATAGAAGACACCGGG 3' and E2m 5'CGACACTGCAGTATACAATGTACAATGCTTTTAAATGCATATCTTAAACAT GCTAAAGTAGCAGCATCACC 3' with pWEB-E2 as template. The bases in italics mismatch the E2 gene and introduce the mutations. The PCR product contains a *Pst*I site (highlighted in bold) at its 3' end. This site, and an *Sst*I site located within the CMV promoter, were used to replace the wild-type E2 sequence in pWEB-E2 with the mutated E2DBDm sequence. The entire PCR product was sequenced using a panel of E2-specific sequencing primers to check for the occurrence of any unwanted mutations.

The plasmid pWEB-E2Ct expresses a truncated E2 protein that lacks the N-terminal amino acids of E2 from 1 to 279 but dimerises and binds DNA normally (Lewis, H., and Gaston, K. (1999) *Submitted*). To create this mutant, HPV 16 sequences between base pairs 3592 and 3852 were amplified by PCR (94°C for 1 minute, 55°C for 1 minute, and 68°C for 1 minute, for 30 cycles) using the primers E2Ct5' 5' GAAACAGAATT**CATGA**ACTGTAATAGTAACACTACACCC 3' and E23' with pWEB-E2 as template. These primers place *Eco*RI restriction sites (bold) at both ends of the product and introduce an ATG translation start codon (italics). The PCR product was cloned into the *Eco*RI site in pWEB and sequenced using E2-specific primers. The plasmid pWEB-E2CtDBDm expresses a DNA binding defective version of E2Ct. This plasmid was produced exactly as described for pWEB-E2Ct except that pWEB-E2DBDm (which comprises full length E2 with the N296A K299A and R304A mutations) was used as template in the PCR reaction.

The 86 amino acid E2Ct (Fig. 11) and E2CtDBDm (Fig. 12) proteins were expressed in *Escherichia coli* XL1-blue cells using expression vector pKK223-3 (Pharmacia Biotech). The sequences encoding E2Ct and 2CtDBDm were excised as *Eco*RI fragments from pWEB-E2Ct and pWEB-E2CtDBDm, respectively, and cloned into a unique *Eco*RI site downstream of the Ptac promoter in pKK223-3. The inserts were sequenced using E2 and pKK223-3-specific primers.

b. Protein purification and circular dichroism spectroscopy.

E. coli XL1-blue cells Stratagene containing either pKK-E2Ct or pKK-E2CtDBDm were grown to an OD_{600nm} of 0.5. Protein expression was then induced with 1mM IPTG and the cells incubated at 37°C overnight. The cells were harvested by centrifugation, resuspended in 50mM Tris-Acetate-EDTA buffer (pH 7.5) containing 1mM MgCl₂ and 1% 2-mercaptoethanol, and then lysed by sonication at 4°C. The cell lysate was cleared by centrifugation (15,000g for 30 minutes at 4°C) then incubated with 0.1% DNase I for 30 minutes at 20°C. The cell extract was dialysed for three hours against 50mM phosphate buffer (pH 5.7) containing 1% 2-mercaptoethanol and then re-centrifuged. The supernatant was loaded onto an S-Sepharose cation exchange medium column equilibrated in 50mM phosphate buffer (pH 5.7) containing 10mM DTT. After washing with 50 column volumes of phosphate buffer, the E2 protein was eluted using a linear gradient of 0.2-1M NaCl in the same buffer over 500ml (at 1ml/minute). Protein peaks (detected by A_{280nm}) were collected and analysed by SDS-PAGE and gel retardation assays (data not shown). Pooled E2 fractions were dialysed against 10 volumes of 50mM phosphate buffer (pH 5.7) containing 10mM DTT for three hours and then applied to a MonoS HR 16/10 cation exchange FPLC column equilibrated in the same buffer. E2 was eluted with a 0.1-1M NaCl gradient and dialysed against 25mM Na phosphate buffer (pH 7.9) containing 1mM DTT for 3 hours before being snap frozen and stored at -70°C. Isoelectric points (pI) and molecular weight values were determined from the amino acid sequences of wild-type (pI 9.7; *Mr* 10016.6) and mutant E2 (pI 9.4; *Mr* 9831.4) using ExPASy Tools. Molecular weights were confirmed on a VG Quattro triple quadrupole mass spectrophotometer with electrospray ionization. Structural integrity was confirmed using far-UV and near-UV circular dichroism spectroscopy on a Jobin Yvon CD6 spectropolarimeter using a 0.05cm path length with a 0.5nm resolution at 1nm/minute.

c. Gel retardation assays.

A double stranded oligonucleotide (100ng) corresponding to the sequence of the HPV 16 E2 site 1 from nucleotides 46 to 65 (5' TTGAACCGAAACCGGTTAGT 3') was end labelled with [γ - 32 P] ATP using T4 polynucleotide kinase (Stratagene). Unincorporated label was removed using a Sephadex G-50 column (Stratagene). Labelled oligonucleotides (10 000 cpm) were incubated with purified proteins in binding buffer (20mM HEPES (pH 7.9), 25mM KCl, 1 mM DTT, 0.1% NP-40, 10% glycerol, 0.5 μ g/ μ l bovine serum albumin, 80ng/ μ l poly[d(I-C)]). After 20 minutes at 20°C, free and bound labelled DNA were resolved on 6% non-denaturing polyacrylamide gels run in 0.5 x TBE and visualised by autoradiography. Heterodimers between wild-type E2Ct and E2CtDBDm were formed by mixing and denaturing the proteins in 3M urea (1 hour at 20°C) and then refolding by dilution to 0.1M urea in binding buffer. The DNA binding activity of the heterodimers was assayed exactly as described above.

d. Cell culture and transfections.

SiHa, C33a and COS-7 cells were maintained in Dulbecco's Modified Eagles Medium (DMEM: Sigma) supplemented with 10% Foetal Bovine Serum (FBS: Sigma) and penicillin (100 000 U/litre) and streptomycin (100mg/litre). NIH 3T3 cells were maintained in DMEM supplemented with 10% Calf Serum (CS:Sigma) and penicillin/streptomycin. HeLa cells were maintained in Minimal Essential Medium (MEM: Sigma) supplemented with 10% FBS, 2mM L-glutamine and penicillin/streptomycin. 866, 873, 877, 915 and 808F cells were maintained in DMEM supplemented with 5% FBS, penicillin/ streptomycin, 2mM L-glutamine, 5 μ g/ml insulin, 0.01 μ g/ml EGF, 0.01 μ g/ml cholera toxin and 0.4 μ g/ml hydrocortisone. All cells were maintained at 37 °C in 5% CO₂.

Prior to transient transfection, cells were seeded at 3x10⁵ cells per well onto coverslips in 6 well plates and incubated overnight to obtain a sub-confluent culture. The liposome based reagents Tfx-50, for SiHa and NIH3T3 cells, and Tfx-20, for all other cell lines, (Promega) were used at a 3:1 liposome:DNA ratio in 1ml serum free media per transfection, according to the manufacturer's instructions. The DNAs used in each transfection are described in the text. After 18 hours (E7 experiments) or 30 hours (E2

experiments), the coverslips were washed in PBS and the cells fixed with 4% paraformaldehyde/PBS at 22°C for 30 minutes. Following further washes with PBS, the cells were stained with bisbenzimidazole (Hoechst No.33258: Sigma) for 30 minutes before being washed in PBS and mounted onto microscope slides in 10µl MOWIOL (Calbiochem).

e. Fluorescence microscopy and imaging.

Fluorescence microscopy was carried out using a Leica DM IRBE inverted epi-fluorescent microscope fitted with FITC and DAPI filter sets and a 20x air objective (Leica). Imaging was carried out using a Leica DM IRBE inverted confocal microscope using a 63x oil objective (Leica) and TCS-NT4 software (Leica).

2) The HPV 16 E2 and E7 proteins induce apoptosis in HeLa cells.

The plasmids pWEB-E2, pWEB-E6, and pWEB-E7 express the HPV 16 E2, E6 and E7 proteins, respectively. Each of these plasmids was transiently transfected in increasing amounts into HeLa cells growing on coverslips using liposomes Fig. 2 shows a representative group of HeLa cells visualised using a 40x oil immersion lens fitted to an epi-fluorescent microscope: (a) Bright field microscopy, (b) GFP fluorescence. (c) DAPI fluorescence. In each experiment the GFP-expressing plasmid pCMX-GFP3 was co-transfected into the cells; pCMX-GFP3 expresses the green fluorescent protein (GFP) and allows transfected cells to be identified by their fluorescence upon excitation through an FITC filter set. Since GFP is expressed uniformly throughout the transfected cell it also allows the assessment of cellular morphology (Fig. 2b). The cells were stained with bisbenzimidazole (Hoechst stain) which enters the nuclei of all of the cells present, regardless of their transfection status, and allows a comparison of chromatin condensation between untransfected cells and transfected cells within the population (Fig. 2c). Individual cells were scored as untransfected or transfected using GFP and then assessed for chromatin condensation and membrane blebbing using Hoechst stain and GFP, respectively. A typical transfected cell that is undergoing apoptosis is indicated in Fig. 2. Membrane blebbing is seen in (a) and (b). Chromatin condensation is seen in (c). The percentage of untransfected cells and transfected cells undergoing apoptosis was determined by counting.

The percentage of apoptotic HeLa cells seen after transient transfection with the E2, and E7 expressing plasmids is shown in Figure 2. In each experiment around 5% of the untransfected cells, and around 5% of the cells transfected with the empty pWEB vector, are apoptotic. Both the E2 and the E7 expression plasmids produced a significant increase in the levels of apoptosis within the transfected population (Fig. 3a and Fig. 3b, respectively). Apoptotic cells in the transfected and untransfected populations were identified as shown in Fig. 2. The transfection was performed in duplicate and repeated three times. These data demonstrate that the HPV 16 E2 and E7 proteins both efficiently induce apoptosis in HeLa cells. We next set out to determine whether these protein can induce apoptosis in other cell lines.

3) E2 and E7 induce apoptosis in both HPV-transformed and non-HPV-transformed cell lines.

We assayed the ability of the HPV 16 E2 and E7 proteins to induce apoptosis in 6 HPV-transformed cell lines and 4 non-HPV transformed cell lines. The results of this comparison are shown in Table 1.

Table 1 E2 and E7 induce apoptosis in a variety of cell lines.

Cell Line	HPV status	Apoptotic Cells (%) [#]		
		Background*	HPV 16 E2	HPV 16 E7
HeLa	HPV 18	5±2	26 ±3	27 ±3
SiHa	HPV 16	5 ±2	44 ±3	46 ±3
866	HPV 16	5 ±2	22 ±2	22 ±2
873	HPV18	7 ±2	35 ±3	24 ±2
877	HPV 18,45	6 ±2	28 ±3	28 ±3
915	HPV 16	7 ±2	33 ±3	23 ±2
C33a	-	8 ±2	9 ±2	8 ±3
COS-7	-	6 ±2	6 ±2	5 ±2
808F	-	6 ±2	26 ±3	20 ±3
NIH3T3	-	6 ±2	25 ±3	20 ±2

The percentage of apoptotic cells was determined as described in the text.

* The background level of apoptosis refers to the untransfected population and the population transfected with the empty pWEB plasmid.

Both E2 and E7 induced high levels of apoptosis in HeLa cells and SiHa cells, an HPV 18- and an HPV 16-transformed cervical carcinoma cell line, respectively. Both E2 and E7 also induced high levels of apoptosis in human 866, 873, 877, and 915 keratinocytes: 866 cells and 915 cells contain HPV 16, 873 cells contain HPV 18, and 877 cells contain both HPV 18 and HPV 45 (Bartholomew, J. *et al* (1997) *Cancer Res.* **57**, 937-942 and P. Stern, unpublished observations). Interestingly, both E2 and E7 failed to induce apoptosis in either C33a cells or COS-7 cells, a non-HPV-transformed cervical carcinoma cell line and an SV40-transformed monkey fibroblast cell line, respectively. However, E2 and E7 did induce high levels of apoptosis in two other HPV-negative cell lines: 808F cells and NIH3T3 cells, a human fibroblast cell line and a mouse fibroblast cell line, respectively. Thus, E2 is capable of inducing apoptosis in at least two HPV-negative cell lines. Another striking feature of these results is that all the cell lines induced to undergo apoptosis by E2, are also induced to undergo apoptosis by E7. Similarly, the cell lines that are not sensitive to E2 expression, are not sensitive to E7 expression. These data suggest that E2 and E7 induce apoptotic cell death via the same pathway, or via pathways that converge at some point.

All of the cell lines that were seen to undergo apoptosis in response to E2 or E7 expression are thought to contain wild-type p53. For example, NIH 3T3 cells contain wild-type p53 and can undergo p53-dependent apoptosis (Chirillo, P. *et al* (1997) *Proc. Natl. Acad. Sci. USA.* **94**, 8162-8167). In contrast, C33a cells contain mutated p53 (Crook, T., *et al* (1991) *Oncogene.* **6** 873-875) and these cells fail to undergo apoptosis in response to either E2 or E7. To determine whether p53 plays a role in E2 and/or E7-induced cell death, we next looked at the effects of a trans-dominant negative p53 mutant and expression of the HPV 16 E6 protein, on the levels of apoptosis in cells expressing these proteins.

4) E2 and E7 induce apoptosis via a p53-dependent pathway.

HeLa cells were transiently transfected with the GFP-expressing plasmid pCMX-GFP3 and either pWEB, pWEB-E2, or pWEB-E7 and either pCB6+p53, which expresses wild-type p53 (wt), or pCB6+p53173L, which expresses mutant p53 (mt). Apoptotic cells were identified as in Fig. 2.

Co-expression of wild-type p53 increased the level of apoptosis induced by both E2 and E7 by almost 50% (compare columns 4 and 5 and 7 and 8 in Fig. 4a). In contrast, co-expression of the trans-dominant negative p53173L mutant decreased the level of apoptosis induced by both E2 and E7 to near the basal level (columns 6 and 9 respectively in Fig. 4a). These data suggest that the apoptosis induced by the HPV 16 E2 and E7 proteins occurs through a p53-dependent pathway. To confirm this conclusion, HeLa cells were transiently co-transfected with pWEB-E2 or pWEB-E7 and either pWEB-E6, or the empty pWEB vector. The HPV 16 E6 protein binds p53 in conjunction with the E3 ubiquitin ligase enzyme E6-AP and this results in the degradation of p53 via a ubiquitin-dependent protease (Scheffner, M. *et al* (1990) *Cell*. **63**. 1129-1136, Huibregtse, J. M. *et al* (1991) *EMBO J.* **10**. 4129-4135). The addition of increasing amounts of the pWEB-E6 plasmid resulted in a gradual decrease in the level of E2-induced apoptosis (Fig. 4b). Similarly, the level of apoptosis induced by the E7 protein was also significantly reduced by the co-expression of E6 (Fig. 4c). In the presence of large amounts of pWEB-E6, the levels of both E2- and E7-induced apoptosis were reduced to around the basal level. Taken together these results firmly establish that functional p53 is required for apoptosis induced by both the HPV 16 E2 protein, and the HPV 16 E7 protein.

5) The DNA binding activity of E2 is not required for the induction of apoptosis.

Although there are several plausible mechanisms whereby E7 over-expression could result in apoptosis, the route from E2 over-expression to apoptosis is unclear. We originally proposed that in SiHa cells, E2 might increase transcription of the integrated E7 oncogene, and that this might result in E7-induced cell death. However, here we have shown that E2 can induce apoptosis in at least 2 non-HPV-transformed cell lines (Table 1). These data imply that E2 does not kill cells simply by activating transcription of E7. To confirm this hypothesis we placed three point mutations within the E2 DNA binding domain (DBD) at

positions known to be important for protein-DNA interactions. The crystal structures of the HPV 16 E2 DBD and the BPV1 E2 DBD-DNA complex suggest that amino acids N296, K299, and R304 within the HPV 16 E2 DBD, are critical for the recognition of specific E2 binding sites (Hegde, R. S. and Androphy, E. J. (1998) *J. Mol. Biol.* **284**. 1479-1489, Hegde, R. S. *et al* (1992) *Nature* **359**. 505-512). Using site-directed mutagenesis we replaced all three of these amino acids with alanines. The mutations were introduced in the context of both the full length E2 protein, and the E2 DNA binding domain alone.

To establish that these mutations abolish DNA binding activity without disrupting the overall folding of the E2 DBD, we expressed both the wild-type DBD and the mutated DBD in bacteria. The plasmid pKK-E2Ct expresses a truncated E2 protein (amino acids 280 to 365) that can dimerise and bind DNA normally (Lewis H. and Gaston, K (1999) *Submitted*). The plasmid pKK-E2CtDBDm expresses the equivalent E2 fragment containing the N296A, K299A, and R304A mutations. The E2Ct and E2CtDBDm proteins were purified from bacteria carrying the respective plasmids (Fig. 5a). Specifically, in the Fig. 5 (a) experiment samples of purified E2Ct and E2CtDBDm were analysed by SDS-PAGE. The sizes of the markers used are indicated in the Figure. In the Fig. 5 (b) and (c) experiment circular dichroism was used to show that the presence of the N296, K299, and R304 mutations did not affect the folding or dimerisation of E2CtDBDm. (d) Increasing amounts (10, 50, and 250nM, respectively) of E2Ct (lanes 2-4) or E2CtDBDm (lanes 5-7) were added to labelled oligonucleotides carrying E2 binding site 1 from the HPV 16 genome: E2(1). Free and bound DNA was separated on a 6% polyacrylamide gel and visualised by autoradiography. The E2Ct-E2(1) complex is indicated by an arrowhead. Circular dichroism (CD) was then used to test whether the presence of the mutations altered the folding or dimerisation of the E2 DBD. The CD spectra for the E2Ct and E2CtDBDm proteins (Fig. 5b and 5c) are very similar. This implies that the mutations have little or no effect on these properties. Fig. 5d shows the results of a gel retardation assay in which increasing amounts of the E2Ct protein (lanes 2-4) or the E2CtDBDm protein (lanes 5-7) were added to labelled oligonucleotides carrying an E2 binding site. As can be seen from the Figure, E2Ct binds tightly to the labelled DNA whereas E2CtDBDm exhibits no detectable binding to this site.

To determine whether the DNA binding activity of E2 is required for the induction of cell death, we transiently transfected HeLa cells with plasmid pCMU-GFP3 expressing either the wild-type full length E2 protein (pWEB-E2), or full length E2 carrying the N296A, K299A, and R304A mutations (pWEB-E2DBDm). Apoptotic cells were identified as shown in Fig. 2. The transfection was performed in duplicate and repeated three times. Somewhat surprisingly, the pWEB-E2 and pWEB-E2DBDm plasmids induced almost identical levels of cell death (Fig. 6). In contrast, the plasmid pWEB-E2Ct, which expresses the E2 DBD alone and therefore lacks the N-terminal transcription activation domain, failed to induce cell death (Fig. 6). Thus, although the sequence-specific DNA binding activity of E2 is not required for the induction of apoptosis in HeLa cells, the N-terminal transcription activation domain is indispensable. To confirm and extend these conclusions we next looked at the ability of E2 heterodimers to induce cell death.

6) Two functional N-terminal domains are required for E2-induced cell death.

The BPV1 E2 and E2-TR proteins have previously been shown to form heterodimers (Barsoum, J. *et al* (1992) *J. Virol.* **66**. 3941-3945). Although these heterodimers are reported to bind DNA *in vitro*, they fail to activate transcription in intact cells (Barsoum, J. *et al* (1992) *J. Virol.* **66**. 3941-3945). In view of this, we wanted to determine whether the HPV 16 E2 and E2Ct proteins would form heterodimers and whether these heterodimers would be capable of inducing cell death. To ascertain whether or not heterodimers could be formed *in vitro*, we mixed a fixed amount of wild-type E2Ct, with increasing amounts of the DNA binding defective E2CtDBDm protein. The amounts of E2Ct and E2CtDBDm indicated in Figure 7a were mixed and then denatured in 3M urea to facilitate the exchange of subunits. After refolding by dilution into 0.1M urea, the proteins were added to labelled oligonucleotides carrying the HPV 16 E2 binding site 1: E2(1). Free and bound DNA was separated on a 6% polyacrylamide gel and visualised by autoradiography. The E2Ct-E2(1) complex is indicated by an arrowhead. As expected, re-folded E2Ct binds to a labelled oligonucleotide carrying an E2 site whereas re-folded E2CtDBDm shows no DNA binding activity (Fig. 7a, lanes 3 and 4, respectively). Adding increasing amounts of E2CtDBDm to a fixed amount of E2Ct resulted in a gradual decline in DNA binding activity (Fig. 7a, lanes 5-8). These data show that at least in this *in vitro* assay, these E2 proteins can form heterodimers.

To investigate the formation of heterodimers in intact cells, HeLa cells were transiently transfected with pWEB-E2 and increasing amounts of the empty pWEB plasmid (open squares), pWEB-E2Ct and increasing amounts of pWEB (filled circles), or pWEB-E2 and increasing amounts of pWEB-E2Ct (filled squares). Apoptotic cells were identified as in Fig. 2 and the transfection was performed in duplicate and repeated three times. As expected, the pWEB-E2 plasmid induced high levels of cell death in the transfected population whereas the pWEB-E2Ct plasmid had no effect (Fig. 7b). However, as increasing amounts of the pWEB-E2Ct plasmid were added to a transfection mixture containing pWEB-E2, the percentage of apoptotic cells in the transfected population showed a steady decline and eventually reached background levels (Fig. 7b). Increasing amounts of the pWEB-E2CtDBDm plasmid also decreased the level of pWEB-E2-induced cell death whereas increasing amounts of the empty pWEB plasmid had no effect (not shown). Taken together these data suggest that heterodimers containing E2 and E2Ct form in intact cells and that these heterodimers are incapable of inducing apoptosis. Thus it appears that the E2 dimer requires two functional N-terminal domains in order to induce cell death.

7) E2 and the immune response

E2 and the immune response to HPV

Previous data are consistent with a possible role for E2 immunity in the control of HPV infection in cervical neoplasia (Rocha-Zavaleta *et al.*, 1997 *Brit. J. Cancer* **75**, 1144-1150). Induced immunity to E2 could be protective and would in principle target the earliest stages of viral expression in the basal/parabasal cells of the cervical epithelium. Stimulating local long lived mucosal immunity would have the advantage over capsid protein based vaccines in eliminating cells with DNA in episomal form which might form the pool (latent state) from which integration events (a major risk factor for progression) may occur subsequently. PV positivity in women can be about 39% in sexually active women aged 15-25. This decreases markedly with age and supports the view that there is an acquired immunity to infection.

The prospect of local delivery of an immunogenic modified E2 protein which can activate an apoptosis pathway would represent a complementary attack on any cervical lesion with both therapeutic and preventative components. This should be relevant to high risk and low risk virus infection including genital and other warts.

An interesting possibility is that the immunogenicity of E2 protein may be enhanced by being bound to its target DNA. This complex might deliver unique epitopes which are recognised by the immune response in natural clearance.

Claims

1. A method of inducing apoptosis of p53-, or p53 mutant- or p53 related gene, positive cells comprising contacting those cells with a PV E2 and/or E7 protein or a functional portion or derivative thereof or supplying to the cells a DNA sequence encoding a PV E2 and/or E7 protein or a functional portion or derivative thereof.
2. A method of killing PV positive cells comprising contacting those cells with a PV E2 and/or E7 protein or a functional portion or derivative thereof or supplying to the cells a DNA sequence encoding a PV E2 and/or E7 protein or a functional portion or derivative thereof.
3. A method of killing cells infected with an oncogenic virus comprising contacting those cells with a PV E2 and/or E7 protein or a functional portion or derivative thereof or supplying to the cells a DNA sequence encoding a PV E2 and/or E7 protein or a functional portion or derivative thereof.
4. A method of killing oncogenic cells or oncogenic precursor comprising contacting those cells with a PV E2 and/or E7 protein or a functional portion or derivative thereof or supplying to the cells a DNA sequence encoding a PV E2 and/or E7 protein or a functional portion or derivative thereof.
5. A method according to claim 1, 2, 3 or 4 in which a substantial proportion of cells in a treated cell population are killed.
6. A method according to any preceding claim in which the cells are infected with HPV.
7. A method according to any preceding claim in which the cells are transformed by HPV.
8. A method according to claim 6 or 7 in which the HPV is integrated in the cell genome.
9. A method according to claim 6, 7, or 8 in which the HPV is type 16 and/or 18.
10. A method according to any preceding claim in which the cells are mammalian cells.
11. A method according to claim 10 in which the cells are in a mammalian subject
12. A method according to claim 10 or 11 in which the cells are human cells.
13. A method according to any one of claims 1, 2 or 5 to 12 in which the cells are oncogenic cells or precursors thereof.
14. A method according to any preceding claim in which the cells are virally infected.
15. A method according to claim 14 in which the cells are infected with an oncogenic virus.

16. A method according to claim 15 in which the oncogenic virus is an HPV or an adenovirus.
17. A method according to claim 14 in which the cells are infected with HIV or a derivative thereof.
18. A method according to any preceding claim in which an immune response, preferably a mucosal response is induced in the cells or subject.
19. A method according to any preceding claim in which the cells over-express p53 or related gene or a mutant thereof.
20. A method according to any preceding claim in which the derivative or functional portion binds DNA less well than wildtype E2 or E7.
21. A method of treating cervical cancer comprising contacting cervical cells of a subject with E2 and/or E7 or a functional portion thereof or supplying to the cells a DNA sequence encoding a PV E2 and/or E7 protein or a functional portion thereof.
22. A method according to claim 21 in which the subject is human.
23. A method according to claim 21 or 22 including inducing an immunological response in a subject against PV.
24. A method according to any preceding claim in which a portion or derivative of E2 and/or E7 is used in which the portion or derivative is defective in DNA binding compared to wild type E2 and/or E7.
25. A method according to any preceding claim in which the E2 or E7 protein or portion or derivative thereof is complexed with DNA.
26. A PV vaccine comprising at least a portion or derivative of E2 and/or E7.
27. A PV vaccine according to claim 26 in which the E2 or E7 is derived from HPV.
28. A DNA binding-defective variant comprising an E2 or E7 amino acid sequence lacking C terminal portion(s) of a native E2 or E7 sequence.
29. Homodimers comprising the E2 or E7 variants according to claim 28.
30. Heterodimers comprising E2 or E7 variants according to claim 28.
31. A vector comprising a modified E2 or E7 DNA sequence or at least a portion of an E2 or E7 DNA sequence.
32. A vector according to claim 31 in which the E2 or E7 DNA sequence encodes an E2 or E7 derivative which can kill p53 positive cells, PV positive cells, cells infected with an oncogenic virus or oncogenic cells.


33. A vector according to claim 31 or 32 which encodes a polypeptide which will generate an immune response, preferably a mucosal response, in a mammalian cell.
34. A vector according to claim 31, 32, or 33 in which the E2 or E7 DNA sequence encodes an E2 or E7 derivative which can inhibit viral replication.
35. A vector according to claim 34 in which the derivative will inhibit replication of HPV.
36. A vector according to claim 31, 32, 33, or 34 in which the E2 or E7 DNA sequence encodes an E2 derivative which is defective in binding DNA compared to wild type E2 or E7.
37. A nucleotide sequence encoding an E2 or E7 derivative according to claim 28.
38. A nucleotide sequence according to claim 38 in which the sequence is a DNA or RNA sequence.

Methods of Inducing Cell Death

This invention relates to methods of inducing cell death.



Fig. 1







Fig. 2



Fig. 3A

a



b




Fig. 3B

Fig. 4

a




Fig. 4B

b




Fig 4C

C




Fig 5A

a




Fig 5B

b




Fig 5C

C




Fig 5D




Fig. 6






Fig. 7A

a




Fig. 7B

b




Fig. 8

The E2 proteins used in this work




Fig. 9

HPV 16 E2

2755 ATGGAGACTCTTTGCCAACGTTTAAATGTGTGTCAGGACAAAATACTAACACATTATGAA
 -----+-----+-----+-----+-----+-----+-----
 M E T L C Q R L N V C Q D K I L T H Y E

2815 AATGATAGTACAGACCTACGTGACCATATAGACTATTGGAAACACATGCGCCTAGAATGT
 -----+-----+-----+-----+-----+-----+-----
 N D S T D L R D H I D Y W K H M R L E C

GCTATTTATTACAAGGCCAGAGAAATGGGATTTAAACATATTAACCACCAAGTGGTGCCA

2875 -----+-----+-----+-----+-----+-----+-----
 A I Y Y K A R E M G F K H I N H Q V V P

2935 ACACTGGCTGTATCAAAGAATAAAGCATTACAAGCAATTGAACTGCAACTAACGTTAGAA
 -----+-----+-----+-----+-----+-----+-----
 T L A V S K N K A L Q A I E L Q L T L E

2995 ACAATATATAACTCACAATATAGTAATGAAAAGTGGACATTACAAGACGTTAGCCTTGAA
 -----+-----+-----+-----+-----+-----+-----
 T I Y N S Q Y S N E K W T L Q D V S L E

3055 GTGTATTTAACTGCACCAACAGGATGTATAAAAAACATGGATATACAGTGGAAGTGCAG
 -----+-----+-----+-----+-----+-----+-----
 V Y L T A P T G C I K K H G Y T V E V Q

3115 TTTGATGGAGACATATGCAATACAATGCATTATACAAACTGGACACATATATATATTTGT
 -----+-----+-----+-----+-----+-----+-----
 F D G D I C N T M H Y T N W T H I Y I C

3175 GAAGAAGCATCAGTAAGTGTGGTAGAGGGTCAAGTTGACTATTATGGTTTATATTATGTT
 -----+-----+-----+-----+-----+-----+-----
 E E A S V T V V E G Q V D Y Y G L Y Y V

3235 CATGAAGGAATACGAACATATTTTGTGCAGTTTAAAGATGATGCAGAAAAATATAGTAA
 -----+-----+-----+-----+-----+-----+-----
 H E G I R T Y F V Q F K D D A E K Y S K

3295 AATAAAGTATGGGAAGTTCATGCGGGTGGTCAGGTAATATTATGTCCTACATCTGTGTTT
 -----+-----+-----+-----+-----+-----+-----
 N K V W E V H A G G Q V I L C P T S V F

3355 AGCAGCAACGAAGTATCCTCTCCTGAAATTATTAGGCAGCACTTGGCCAACCACCCCGCC
 -----+-----+-----+-----+-----+-----+-----
 S S N E V S S P E I I R Q H L A N H P A

3415 GCGACCCATACCAAAGCCGTCGCCTTGGGCACCGAAGAAACACAGACGACTATCCAGCGA
 -----+-----+-----+-----+-----+-----+-----

A T H T K A V A L G T E E T Q T T I Q R

3475 CCAAGATCAGAGCCAGACACCGGAAACCCCTGCCACACCACTAAGTTGTTGCACAGAGAC
-----+-----+-----+-----+-----+-----+-----
P R S E P D T G N P C H T T K L L H R D

3535 TCAGTGGACAGTGCTCCAATCCTCACTGCATTTAACAGCTCACACAAAGGACGGATTAAC
-----+-----+-----+-----+-----+-----+-----
S V D S A P I L T A F N S S H K G R I N

3595 TGTAATAGTAACACTACACCCATAGTACATTTAAAAGGTGATGCTAATACTTTAAAATGT
-----+-----+-----+-----+-----+-----+-----
C N S N T T P I V H L K G D A N T L K C

3655 TTAAGATATAGATTTAAAAAGCATTGTACATTGTATACTGCAGTGTCTGTCTACATGGCAT
-----+-----+-----+-----+-----+-----+-----
L R Y R F K K H C T L Y T A V S S T W H

3715 TGGACAGGACATAATGTAAACATAAAAAGTGCAATTGTTACACTTACATATGATAGTGAA
-----+-----+-----+-----+-----+-----+-----
W T G H N V K H K S A I V T L T Y D S E

3775 TGGCAACGTGACCAATTTTTGTCTCAAGTTAAAATACCAAAAACACTATTACAGTGTCTACT
-----+-----+-----+-----+-----+-----+-----
W Q R D Q F L S Q V K I P K T I T V S T

3835 GGATTTATGTCTATATGA
-----+-----+----- 3852
G F M S I * -

Fig 10

HPV 16 E2DBDm

ATGGAGACTCTTTGCCAACGTTTAAATGTGTGTCAGGACAAAATACTAACACATTATGAA
 2755 -----+-----+-----+-----+-----+-----+-----
 M E T L C Q R L N V C Q D K I L T H Y E

AATGATAGTACAGACCTACGTGACCATATAGACTATTGGAAACACATGCGCCTAGAATGT
 2815 -----+-----+-----+-----+-----+-----+-----
 N D S T D L R D H I D Y W K H M R L E C

GCTATTTATTACAAGGCCAGAGAAATGGGATTTAAACATATTAACCACCAAGTGGTGCCA
 2875 -----+-----+-----+-----+-----+-----+-----
 A I Y Y K A R E M G F K H I N H Q V V P

ACACTGGCTGTATCAAAGAATAAAGCATTACAAGCAATTGAACTGCAACTAACGTTAGAA
 2935 -----+-----+-----+-----+-----+-----+-----
 T L A V S K N K A L Q A I E L Q L T L E

ACAATATATAACTCACAAATATAGTAATGAAAAGTGGACATTACAAGACGTTAGCCTTGAA
 2995 -----+-----+-----+-----+-----+-----+-----
 T I Y N S Q Y S N E K W T L Q D V S L E

GTGTATTTAACTGCACCAACAGGATGTATAAAAAACATGGATATACAGTGGAAAGTGCAG
 3055 -----+-----+-----+-----+-----+-----+-----
 V Y L T A P T G C I K K H G Y T V E V Q

TTTGATGGAGACATATGCAATACAATGCATTATACAAACTGGACACATATATATATTTGT
 3115 -----+-----+-----+-----+-----+-----+-----
 F D G D I C N T M H Y T N W T H I Y I C

GAAGAAGCATCAGTAACTGTGGTAGAGGGTCAAGTTGACTATTATGGTTTATATTATGTT
 3175 -----+-----+-----+-----+-----+-----+-----
 E E A S V T V V E G Q V D Y Y G L Y Y V

CATGAAGGAATACGAACATATTTTGTGCAGTTTAAAGATGATGCAGAAAAATATAGTAAA
 3235 -----+-----+-----+-----+-----+-----+-----
 H E G I R T Y F V Q F K D D A E K Y S K

AATAAAGTATGGGAAGTTCATGCGGGTGGTCAGGTAATATTATGTCCTACATCTGTGTTT
 3295 -----+-----+-----+-----+-----+-----+-----
 N K V W E V H A G G Q V I L C P T S V F

AGCAGCAACGAAGTATCCTCTCCTGAAATTATTAGGCAGCACTGGCCAACCAACCCCGCC
 3355 -----+-----+-----+-----+-----+-----+-----
 S S N E V S S P E I I R Q H L A N H P A

GCGACCCATACCAAAGCCGTCGCCTTGGGCACCGAAGAAACACAGACGACTATCCAGCGA
 3415 -----+-----+-----+-----+-----+-----+-----
 A T H T K A V A L G T E E T Q T T I Q R



CCAAGATCAGAGCCAGACACCGGAAACCCCTGCCACACCACTAAGTTGTTGCACAGAGAC
 3475 -----+-----+-----+-----+-----+-----
 P R S E P D T G N P C H T T K L L H R D

TCAGTGGACAGTGCTCCAATCCTCACTGCATTTAACAGCTCACACAAAGGACGGATTAAAC
 3535 -----+-----+-----+-----+-----+-----
 S V D S A P I L T A F N S S H K G R I N

TGTAATAGTAACACTACACCCATAGTACATTTAAAAGGTGATGCTgctACTTTAgcatGT
 3595 -----+-----+-----+-----+-----+-----
 C N S N T T P I V H L K G D A A T L A C

TTAAGATATgcatTTTAAAAGCATTGTACATTGTATACTGCAGTGTCTGCTACATGGCAT
 3655 -----+-----+-----+-----+-----+-----
 L R Y A F K K H C T L Y T A V S S T W H

TGGACAGGACATAATGTAAACATAAAAAGTGCAATTGTTACACTTACATATGATAGTGAA
 3715 -----+-----+-----+-----+-----+-----
 W T G H N V K H K S A I V T L T Y D S E

TGGCAACGTGACCAATTTTTGTCTCAAGTTAAAATACCAAAAACCTATTACAGTGTCTACT
 3775 -----+-----+-----+-----+-----+-----
 W Q R D Q F L S Q V K I P K T I T V S T

GGATTTATGTCTATATGA
 3835 -----+-----+--- 3852
 G F M S I * -

Fig 11

E2Ct

ATGAACTGTAATAGTAACACTACACCCATAGTACATTTAAAAGGTGATGCTAATACTTTAAAATGT

-----+-----+-----+-----+-----+-----+-----+-----
M N C N S N T T P I V H L K G D A N T L K C

TTAAGATATAGATTTAAAAAGCATTGTACATTGTATACTGCAGTGTCTGCTACATGGCAT

-----+-----+-----+-----+-----+-----+-----+-----
L R Y R F K K H C T L Y T A V S S T W H

TGGACAGGACATAATGTAAACATAAAAGTGCAATTGTTACACTTACATATGATAGTGAA

-----+-----+-----+-----+-----+-----+-----+-----
W T G H N V K H K S A I V T L T Y D S E

TGGCAACGTGACCAATTTTTGTCTCAAGTTAAAATACCAAAACTATTACAGTGTCTACT

-----+-----+-----+-----+-----+-----+-----+-----
W Q R D Q F L S Q V K I P K T I T V S T

GGATTTATGTCTATATGA

-----+-----+----- 3852

G F M S I * -

Fig 12

E2CtDBDm

ATGAACTGTAATAGTAACACTACACCCATAGTACATTTAAAAGGTGATGCTgctACTTTAgcaTGT

-----+-----+-----+-----+-----+-----+-----
M N C N S N T T P I V H L K G D A A T L A C

TTAAGATATgcaTTTAAAAAGCATTGTACATTGTATACTGCAGTGTTCGTCTACATGGCAT

-----+-----+-----+-----+-----+-----+-----
L R Y A F K K H C T L Y T A V S S T W H

TGGACAGGACATAATGTAAAACATAAAAGTGCAATTGTTACACTTACATATGATAGTGAA

-----+-----+-----+-----+-----+-----+-----
W T G H N V K H K S A I V T L T Y D S E

TGGCAACGTGACCAATTTTTGTCTCAAGTTAAAATACCAAAAACACTATTACAGTGTCTACT

-----+-----+-----+-----+-----+-----+-----
W Q R D Q F L S Q V K I P K T I T V S T

GGATTTATGTCTATATGA

-----+-----+--- 3852
G F M S I * -

